Cost of retained fetal membranes for dairy herds in the United States.

OBJECTIVE To estimate the cost of a case of retained fetal membranes (RFM) for dairy herds in the United States. DESIGN Deterministic computer-based spreadsheet analysis. SAMPLE Inputs from published studies and reports. PROCEDURES Economic losses attributable to RFM were direct (reduction in milk yield and longer interval until pregnancy) and indirect (increased risk of developing clinical disease and increased culling risk). Cost attributable to milk loss was calculated as the mean marginal loss of milk production for cows with RFM and cows with RFM complicated by metritis. Cost of the increased risk of developing clinical disease because of RFM was a product of the cost of each clinical disease and the risk of each clinical disease attributable to RFM. Cost attributable to reduced reproductive performance was a function of a longer interval until pregnancy, whereas cost for increased culling attributable to RFM was associated with the market value of cull cows and replacement heifers as well as herd turnover rate. RESULTS Cost of a case of RFM determined by use of default inputs was $386 (reduction in milk yield, $287; increased time until pregnancy, $73; increased disease risk, $25; and increased culling risk, $1). Sensitivity analysis revealed that milk and feed prices were the most influential inputs. CONCLUSIONS AND CLINICAL RELEVANCE Cost of a case of RFM, including uncomplicated cases, was substantial and comparable to that for other common clinical diseases during the transition period. Preventive measures during the nonlactating period should be considered to minimize the incidence of RFM.

The cost of a case of subclinical ketosis in Canadian dairy herds.

The objective of this study was to develop a model to estimate the cost of a case of subclinical ketosis (SCK) in Canadian dairy herds. Costs were derived from the default inputs, and included increased clinical disease incidence attributable to SCK, $76; longer time to pregnancy, $57; culling and death in early lactation attributable to SCK, $26; milk production loss, $44. Given these figures, the cost of 1 case of SCK was estimated to be $203. Sensitivity analysis showed that the estimated cost of a case of SCK was most sensitive to the herd-level incidence of SCK and the cost of 1 day open. In conclusion, SCK negatively impacts dairy herds and losses are dependent on the herd-level incidence and factors included in the calculation.

Coût d'un cas d'acétonémie subclinique dans les troupeaux laitiers canadiens. L'objectif de cette étude consistait à développer un modèle pour estimer le coût d'un cas d'acétonémie subclinique (ASC) dans les troupeaux laitiers canadiens. Les coûts ont été dérivés des valeurs par défaut et comprenaient l'incidence accrue de maladie clinique attribuable à l'ASC, 76 $; un délai plus long avant la gestation, 57 $; la réforme et la mort au début de la lactation attribuable à l'ASC, 26 $; la perte de production laitière, 44 $. Compte tenu de ces chiffres, le coût de 1 cas d'ASC a été estimé à 203 $. Une analyse de sensibilité a montré que le coût estimé d'un cas d'ASC était le plus sensible à l'incidence de l'ASC au niveau du troupeau et au coût d'une journée ouvrable. En conclusion, l'ASC a un impact négatif sur les troupeaux laitiers et les pertes dépendent de l'incidence au niveau du troupeau et des facteurs inclus dans le calcul.(Traduit par Isabelle Vallières).

Economic value of ionophores and propylene glycol to prevent disease and treat ketosis in Canada.

A partial budget model was developed to evaluate the economic value of Rumensin Controlled Release Capsule (CRC) boluses when administered before calving to reduce disease and increase milk production. After accounting for disease incidences in a herd and the percentage by which Rumensin CRC can reduce them, and the increase in milk production attributable to administration of Rumensin CRC, the return on investment (ROI) per lactation was 4:1. Another partial budget model was developed to estimate the economic value of propylene glycol (PG) to treat ketosis when diagnosed by 3 different cow-side tests or when administered to all cows without using any cow-side testing. After accounting for the sensitivity and specificity of each test, ROI per lactation ranged from 2:1 to 4:1. The ROI was 2:1 when no cow-side testing was used. In conclusion, prevention of diseases that occur in the postpartum period and treatment of ketosis after calving yielded a positive ROI that varies based on disease incidence and method of diagnosis.

Valeur économique des ionophores et du propylèneglycol pour prévenir la maladie et traiter l'acétonémie au Canada. Un modèle de budget partiel a été développé pour évaluer la valeur économique des bolus de capsules à libération contrôlée (CLC) de Rumensin lors de l'administration avant le vêlage afin de réduire les maladies et d'accroître la production de lait. Après avoir tenu compte de l'incidence des maladies dans un troupeau et du pourcentage par lequel la CLC de Rumensin peut les réduire et de l'augmentation de la production de lait attribuable à l'administration de la CLC de Rumensin, le rendement du capital investi (RCI) par lactation était de 4:1. Un autre modèle de budget partiel a été développé pour estimer la valeur économique du propylèneglycol (PG) afin de traiter l'acétonémie lors du diagnostic par 3 tests différents pour les vaches ou lors de l'administration à toutes les vaches sans le recours à des tests auprès des vaches. Après avoir tenu compte de la sensibilité et de la spécificité de chaque test, le RCI par lactation s'échelonnait de 2:1 à 4:1. Le RCI était de 2:1 lorsqu'aucun test auprès des vaches n'était utilisé. En conclusion, la prévention des maladies qui se produit dans la période postpartum et le traitement de l'acétonémie après le vêlage a donné un RCI positif qui varie selon l'incidence de maladies et la méthode de diagnostic.(Traduit par Isabelle Vallières).

Randomized controlled field trial to assess efficacy of a Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis.

OBJECTIVE: To evaluate efficacy of a recombinant Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK). ANIMALS: 107 beef steers. PROCEDURES: 2 groups of calves were inoculated SC with an immunostimulating complex (ISCOM) matrix adjuvant (control group; n = 54) or a recombinant M bovis pilin-cytotoxin-M bovoculi cytotoxin subunit antigen with the ISCOM matrix adjuvant (vaccine group; 53); calves received booster injections 21 days later. Calves were examined once weekly for 16 weeks. Investigators and herd managers were not aware of the inoculum administered to each calf throughout the trial. Primary outcome of interest was the cumulative proportion of calves that developed IBK. Serum samples were obtained before inoculation (day 0) and on days 42 and 112. Serum hemolysin-neutralizing titers against native M bovis and M bovoculi cytotoxin were determined. RESULTS: No difference was detected between groups for the cumulative proportion of calves that developed IBK at weeks 8 and 16 after inoculation. Non-IBK-affected calves in the vaccine group had a significantly higher fold change in serum hemolysin-neutralizing titer against native M bovoculi cytotoxin from day 0 to 42 compared to control calves. CONCLUSIONS AND CLINICAL RELEVANCE: The M bovis pilin-cytotoxin-M bovoculi cytotoxin subunit vaccine with the ISCOM matrix adjuvant was not effective at preventing naturally occurring IBK. It is likely that the incorporation of additional protective antigens in a recombinant Moraxella spp subunit vaccine will be required to yield a product that can be used for effective immunization of cattle against IBK.